التفاصيل البيبلوغرافية
| العنوان: |
Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients. |
| المؤلفون: |
Yoshimoto, Takanori, Oshima, Tadayuki, Fukada, Takashi, Imamura, Nobuko, Nakanishi, Takashi, Ebisutani, Nobuhiko, Morishita, Daisuke, Mieno, Masatoshi, Nakai, Keisuke, Sei, Hiroo, Kitayama, Yoshitaka, Eda, Hirotsugu, Okugawa, Takuya, Tomita, Toshihiko, Fukui, Hirokazu, Shinzaki, Shinichiro |
| المصدر: |
International Journal of Clinical Oncology; Feb2024, Vol. 29 Issue 2, p142-148, 7p |
| مصطلحات موضوعية: |
ESOPHAGEAL cancer, FILGRASTIM, NEOADJUVANT chemotherapy, DOCETAXEL, CANCER patients |
| مستخلص: |
Background: Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy is a new standard for locally advanced esophageal squamous cell carcinoma. The optimal timing of pegfilgrastim with the DCF regimen to prevent febrile neutropenia (FN) remains controversial. The effectiveness of concomitant pegfilgrastim administration with continuous 5-fluorouracil (5-FU) infusion in the DCF regimen was therefore assessed. Methods: All patients who received neoadjuvant DCF for esophageal cancer were retrospectively assessed. Patients who had been scheduled to receive pegfilgrastim on days 3–5 (early group) or days 7–9 (regular group) of the DCF regimen were included. Uni- and multivariate analyses were used to assess risk factors for FN. Results: Eighty-eight patients were included in the analysis. The 26 patients in the early group received pegfilgrastim as scheduled. In the 62 patients of the regular group, 51 received pegfilgrastim at a median of 7 days after starting DCF chemotherapy. However, 11 patients in the regular group could not receive pegfilgrastim. Twenty-two patients of the regular group and 2 patients of the early group developed FN after the first session of DCF. Early administration of pegfilgrastim and grade 4 neutropenia were significantly associated with onset of FN, with multivariate analysis identifying early administration of pegfilgrastim as an independent preventive factor and grade 4 neutropenia as a risk factor, after adjusting for sex and age. Conclusion: Early pegfilgrastim administration is a safe approach that reduces the incidence of FN in DCF therapy. Using pegfilgrastim with continuous 5-FU infusion in the DCF regimen represents a reasonable option to prevent FN. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Clinical Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
